TAP regimen: Difference between revisions
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AV}} | {{CMG}}; {{AE}} {{AV}} | ||
{{SK}} | {{SK}} Taxol-Anthracycline-Platinol regimen | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[ | {{PAGENAME}} refers to a regimen consisting of [[Paclitaxel| paclitaxel (Taxol)]], [[anthracycline]], and [[Cisplatin|cisplatin (Platinol)]] used to treat [[endometrial cancer]].<ref name="pmid15169803">{{cite journal| author=Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR et al.| title=Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. | journal=J Clin Oncol | year= 2004 | volume= 22 | issue= 11 | pages= 2159-66 | pmid=15169803 | doi=10.1200/JCO.2004.07.184 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15169803 }} </ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|T| | {{chemo|T|Paclitaxel (Taxol)}} | ||
{{chemo|A|Anthracycline}} | {{chemo|A|Anthracycline}} | ||
{{chemo|P| | {{chemo|P|Cisplatin (Platinol)}} | ||
==Indications== | ==Indications== | ||
* [[Endometrial cancer]] | * [[Endometrial cancer]]<ref name="pmid15169803">{{cite journal| author=Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR et al.| title=Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. | journal=J Clin Oncol | year= 2004 | volume= 22 | issue= 11 | pages= 2159-66 | pmid=15169803 | doi=10.1200/JCO.2004.07.184 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15169803 }} </ref> | ||
==References== | ==References== | ||
Latest revision as of 18:31, 31 March 2015
|
WikiDoc Resources for TAP regimen |
|
Articles |
|---|
|
Most recent articles on TAP regimen Most cited articles on TAP regimen |
|
Media |
|
Powerpoint slides on TAP regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on TAP regimen at Clinical Trials.gov Clinical Trials on TAP regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on TAP regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on TAP regimen Discussion groups on TAP regimen Patient Handouts on TAP regimen Directions to Hospitals Treating TAP regimen Risk calculators and risk factors for TAP regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for TAP regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Taxol-Anthracycline-Platinol regimen
Overview
TAP regimen refers to a regimen consisting of paclitaxel (Taxol), anthracycline, and cisplatin (Platinol) used to treat endometrial cancer.[1]
Regimen
TPaclitaxel (Taxol)
AAnthracycline
PCisplatin (Platinol)
Indications
References
- ↑ 1.0 1.1 Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR; et al. (2004). "Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study". J Clin Oncol. 22 (11): 2159–66. doi:10.1200/JCO.2004.07.184. PMID 15169803.